Acute Intermittent Porphyria during Pregnancy: A Case Outlining the Safety of Administering Hematin Infusions.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 3759-3759
Author(s):  
Raymond J. Jensen

Abstract Background: Acute Intermittent Porphyria (AIP) is one of the genetic disorders of heme biosynthesis characterized by acute life-threatening attacks of nonspecific neurologic symptoms (1). Gastrointestinal symptoms include abdominal pain, nausea, and vomiting. Neurologic symptoms include pain in extremities, back, chest, or head. Little has been written on pregnancy and porphyria. Neilson and Neilson (1985) (2) reviewed literature for the outcome of pregnancy in porphyria and was able to gather data on 76 pregnancies occurring among 40 patients. They report AIP attacks in 95% of patients. Case Report: The subject is a 35 year-old female, who underwent 2 previous pregnancies. In each pregnancy, she experienced acute episodes of AIP and received intravenous (IV) hematin. The patient was diagnosed in 1995 and became pregnant in 1998. During pregnancy # 1, at 23 wks gestation, the patient presented to the ER and was admitted with AIP. Symptoms included severe abdominal pain and nausea and vomiting. She received 165mg of hematin IV daily 3 days and then was discharged when symptoms resolved. At 25 wks gestation, the patient was admitted for AIP and received 4 doses of hematin. The patient was discharged after 4 days, when symptoms abated. At 32 wks gestation, the patient was admitted for the third time with AIP and given 3 doses of hematin. Her symptoms were included acute abdominal pain, back pain and uncontrolled nausea and vomiting. The patient received a total of 13 doses of hematin during her 4 admissions. The baby was delivered vaginally at term with normal APGAR scores and normal birth weight. The patient was negative for hepatitis and HIV. During pregnancy # 2, the patient presented to the ER at 26 wks gestation. Symptoms included severe abdominal and back pain, uncontrolled nausea and vomiting and upper extremity weakness. Patient received 220mg of hematin and was discharged later that day when symptoms subsided. The patient returned to the ER at 28 wks gestation with complaints of severe abdominal pain, back pain, nausea and vomiting. Patient again received 220mg of hematin but was admitted to the hospital for IV hematin once a day for three days. At 30 wks gestation, the patient presented to the ER with acute abdominal pain, nausea and vomiting and was given 220mg and was discharged later that day. At 32 wks gestation, the patient entered the ER with upper and lower abdominal pain. She received 220 mg of hematin and later was discharged. The patient delivered a healthy baby at 35 weeks gestation. The baby had a normal APGAR and normal birth weight. During her last trimester, the patient received a total of 6 doses of hematin during her second pregnancy. The patient continues to be negative for hepatitis and HIV. Conclusion: Hematin is safe for pregnant women and the fetus. Hematin effectively treated symptoms of AIP. Hematin Dosing Total # Hematin Doses During Pregnancy Dosing/Hematin Infusion Symptoms Pregnancy # 1 13 165 mg Abdominal and Back Pain, Nausea, Vomiting Pregnancy # 2 6 220 mg Abdominal and Back Pain, Nausea, Vomiting Baby Weight Milestones 2 Weeks Check Up 2 Months Check Up 4 Months Check Up Baby 1 6.3 lbs 9.0 lbs 12.0 lbs Baby 2 6.5 lbs 9.1 lbs 11.2 lbs

2017 ◽  
Vol 19 (2) ◽  
pp. 95
Author(s):  
Hetriana Leksananingsih ◽  
Slamet Iskandar ◽  
Tri Siswati

Background: Riskesdas in 2013 showed that Yogyakarta (DIY) had a prevalence of stunted new kid in school is less than the national average, which is 14.9% (MOH, 2013). Stunted or short, is a linear growth retardation has been widely used as an indicator to measure the nutritional status of individuals and community groups. Stunted can be influenced by several factors: birth weight, birth length match and genetic factors. Objective: To determine the weight, length of low birth weight and genetic factors as predictors of the occurrence of stunted on elementary school children. Methods: The study was a case control analytic. Research sites in SD Muhammadiyah Ngijon 1 Subdistrict Moyudan. The study was conducted in May and June 2015. The subjects were school children grade 1 to grade 5 the number of cases as many as 47 children and 94 control children. With the inclusion criteria of research subjects willing to become respondents, was present at the time of the study, they have a father and mother, and exclusion criteria have no data BB and PB birth, can not stand upright. The research variables are BBL, PBL, genetic factors and TB / U at this time. Data were analyzed by chi-square test and Odd Ratio (OR) calculation. Results: In case group as much as 91.5% of normal birth weight and length of 80.9% of normal birth weight, most of the height of a normal mother and father as many as 85.1%. In the control group as much as 78.7% of normal birth weight and 61.7% were born normal body length, height mostly normal mom and dad that 96.7% of women and 90.4% normal normal father. Statistical test result is no significant correlation between height mothers with stunted incidence in school children, and the results of chi-square test P = 0.026 with value Odd Ratio (OR) of 3.9 and a range of values from 1.091 to 14.214 Cl95%. Conclusion: High maternal body of mothers can be used as predictors of the occurrence of stunted school children and mothers with stunted nutritional status have 3.9 times the risk of having children with stunted nutritional status.


2021 ◽  
pp. 097321792199140
Author(s):  
Rimjhim Sonowal ◽  
Anamika Jain ◽  
V. Bhargava ◽  
H.D. Khanna ◽  
Ashok Kumar

Objective: The objective of this study was to evaluate the serum levels of various antioxidants, namely, vitamin A and E, superoxide dismutase (SOD), catalase, and glutathione peroxidase (GPx) in the cord blood of term low birth weight (LBW) neonates who required delivery room resuscitation (DRR). Materials and Methods: This case control study included 37 term LBW neonates who needed DRR as cases and 44 term neonates as controls (15 term LBW and 29 term normal birth weight) who did not require resuscitation at birth. Neonates suffering from major congenital malformations, infection, or hemolytic disease were excluded. Standard methods were used to measure the levels of vitamin A, vitamin E, SOD, catalase, and GPx levels in the cord blood. Results: Vitamin A and E levels were significantly low in cases compared to term LBW controls as well as term normal birth weight controls. Levels of SOD, GPx, and catalase were comparable in different study groups. Conclusion: Our study shows that term LBW neonates requiring DRR had significantly low levels of vitamin A and E in their cord blood. This might compromise their ability to tolerate oxidative stress during DRR.


1985 ◽  
Vol 110 (1) ◽  
pp. 32-35 ◽  
Author(s):  
G. Thiériot-Prévost ◽  
F. Daffos ◽  
F. Forestier

Abstract. The serum level of radioimmunoassayable somatomedin-C and the bioassayable growth-promoting activity evaluated by the stimulating effect of serum upon thymidine incorporation into activated lymphocytes have been measured in the blood of term human foetuses. Comparison between those with a low birth weight and those with normal birth weight has shown that small-forgestational-age subjects have lower somatomedin-C (0.31 ± 0.03 vs 0.52 ± 0.03) and thymidine activity (1.03 ± 0.11 vs 1.50 ± 0.07) (P< 0.001). A positive correlation between somatomedin and thymidine activity was found. There was no difference in serum transferrin levels between both groups. It is suggested that somatomedin, and probably other growth-promoting factors measured by the thymidine bioassay, play a role in regulation of the foetal growth.


2016 ◽  
Vol 20 (8) ◽  
pp. 1559-1568 ◽  
Author(s):  
Teresa A. Hillier ◽  
Kathryn L. Pedula ◽  
Kimberly K. Vesco ◽  
Caryn E.S. Oshiro ◽  
Keith K. Ogasawara

1990 ◽  
Vol 34 (4) ◽  
pp. 251???252
Author(s):  
C. J. BERG ◽  
C. M. DRUSCHEL ◽  
B. J. MCCARTHY ◽  
M. LAVOIE ◽  
R. L. FLOYD

Sign in / Sign up

Export Citation Format

Share Document